Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2009

Fluofarma Teams Up with Roche to Develop Hepatotoxicity Tools

  • Fluofarma signed a multiyear collaboration agreement with Roche focused on developing new tools for predicting the hepatotoxicity of early-stage drug candidates. The companies aim to develop miniaturized cell-based assays using high-throughput flow cytrometry along with computational models for predicting hepatotoxicity and safety profiling of compounds in liver cells.

    Fluofarma platforms include automated confocal microscopy, automated flow cytometry, as well as laser scanning cytometry and combine cell-based assays with large-scale analysis. The company claims its  technologies enable the simultaneous functional analysis of several molecular events in single cells.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »